Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

Trump’s Medicare Pricing Policy Could Mean Big Disruptions to Medical Benefits

Posted by Howard Deutsch on Tue, Nov 13, 2018

Gustavo Poblete co-authored this blog post with Howard Deutsch.

The Trump administration rolled out a significant policy proposal aimed at reducing the prices that Medicare pays for prescription drugs covered under the Part B medical benefit. While the policy is positioned as a “pilot” covering half the country, it will, if implemented as proposed, bring substantially greater disruption to drug pricing, contracting and distribution than purportedly envisioned by the government. Manufacturers with drugs covered under the medical benefit will need to fully reevaluate their strategies to adapt.

Read More

Topics: Howard Deutsch, Medicare Part B, pricing and reimbursement, pharma drug pricing, Trump administration, contracting and distribution strategies, Medicare drug price proposal

Changing the Mindset: Success in Commercializing Rare Disease Drugs

Posted by Michael Thomas on Tue, Apr 26, 2016

There are currently only 314 FDA-approved therapies available among the roughly 7,000 rare diseases that have been identified, according to the Genetic and Rare Diseases Information Center. The global pharmaceutical industry recognizes the unmet need and the opportunity to solve the challenges associated with patients with rare diseases. Current and future pipeline assets offer the pharmaceutical industry an opportunity to bring to market the type of life-changing therapies for patients that add true value where hope is limited.

Read More

Topics: rare diseases, Michael Thomas, organizational alignment, WODC, FDA, pricing and reimbursement

Subscribe to The Active Ingredient


Subscribe to receive email notifications whenever new blog posts are published.